Haematology 2018

Conclusions (2)

• Evidence of synergy between RT and checkpoint inhibition is strong in preclinical lymphoma models with “high” T cell infiltrates or immunologically “hot” tumours • Studies in HL of RT and anti-PD1 mAb underway • Studies in NHL of RT and other immunoregulatory agents ongoing • Currently there are opportunities to exploit the potential of RT and immunoregulatory agents in other lymphomas • Need well planned studies with high quality RTQA and carefully record efficacy and toxicity